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Background/Introduction
Aortic Stenosis (AS) is the most frequent valvular
pathology in the developed world. Whilst much is
known about its pathogenesis and treatment, a paucity
of data exists on the prevalence and number of patients
eligible for valve replacement.
Aims/Objectives
To quantify prevalence, treatment eligibility and post-
operative survival in patients with AS.
Method
A systematic search was conducted across PubMed and
EMBASE for studies evaluating prevalence, severity, deci-
sion-making and survival in AS patients. Studies were
selected using a priori defined criteria reviewed by two
independent investigators. Prevalence rates [95%CI] were
calculated and pooled using fixed and random-effects
models (statistical heterogeneity evaluated via X2 and I2).
Subsequently, Monte Carlo methods with beta distribu-
tions and 2012 population data were utilised to assess
eligibility per treatment option (using ESC indications).
Results
Fifty-four studies were included encompassing 52,951
patients across 5 domains: prevalence, severity, symptom
status, treatment and outcome. Pooled prevalence in the
general population aged 55-74yrs and >75yrs was 2.9%
[1.5-4.3%] and 13.6% [8.3-18.9%], respectively. Of these,
21.6% [19.1-24.2%] had severe AS with 71.1% [62.7-
79.4%] symptomatic. SAVR was performed in 57.1%
[47.7-66.6%] of symptomatic patients and 28.2% [16.6-
39.7%] of asymptomatic patients. In non-operated
asymptomatic patients, 44.7% [36.7-53.0%] progressed to
SAVR within 2yrs. Regardless of symptoms, SAVR was
associated with a 3-fold increase in survival within 2yrs
(OR: 3.6 and 3.9). In high-risk/inoperable severe symp-
tomatic patients aged ≤75yrs, 39.9% [31.4-48.4%]
received TAVR. On Monte Carlo simulation, there are
9,187,586 [6,988,043-11,629,367] Europeans aged ≤55yrs
with AS. Of these, 1,984,666 [1,494,584-2,550,594] have
severe AS with 1,178,766 [878,802-1,528,812] eligible for
SAVR and 234,934 [149,699-340,960] eligible for TAVR.
Discussion/Conclusion
Within current ESC guidelines, approximately 1.2 million
Europeans aged ≤55yrs are candidates for SAVR with an
additional 230,000 patients aged ≤75yrs eligible for
TAVR.
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